Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 10:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Solriamfetol Placebo Clear all
Recruiting Phase 3 Interventional

Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)

NCT07717892
View directory record Official record
Conditions
ADHD
Interventions
Solriamfetol Dose A, Solriamfetol Dose B, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
24
States / cities
Dothan, Alabama • Little Rock, Arkansas • Irvine, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 12, 2026, 10:05 AM EDT
Completed Phase 2 Interventional

RECOVER-SLEEP: Platform Protocol

NCT06404086
View directory record Official record
Conditions
Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance
Interventions
Modafinil, Modafinil Placebo, Solriamfetol, Solriamfetol Placebo, Melatonin, Melantonin Placebo, Tailored lighting (TL) Active, Tailored lighting (TL) Placebo
Drug · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
47
States / cities
Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 12, 2026, 10:05 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness

NCT01485770
View directory record Official record
Conditions
Narcolepsy
Interventions
ADX-N05, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
10
States / cities
Phoenix, Arizona • St. Petersburg, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2021 · Synced Sep 12, 2026, 10:05 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy

NCT01681121
View directory record Official record
Conditions
Narcolepsy
Interventions
ADX-N05, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Redwood City, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Sep 12, 2026, 10:05 AM EDT
Recruiting Phase 3 Interventional

Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

NCT07484217
View directory record Official record
Conditions
Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Interventions
Solriamfetol 150 MG, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
40
States / cities
Tucson, Arizona • Bellflower, California • Chino, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 12, 2026, 10:05 AM EDT
Completed Phase 4 Interventional

Solriamfetol and CBT-I in Patients With Insomnia Disorder

NCT05838430
View directory record Official record
Conditions
Insomnia
Interventions
Solriamfetol 75 MG, Cognitive Behavioral Therapy for Insomnia (CBT-I), Monitoring, Placebo
Drug · Behavioral · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
25 Years to 60 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 12, 2026, 10:05 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Trial of Solriamfetol in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

NCT04622293
View directory record Official record
Conditions
Chronic Fatigue Syndrome, Myalgic Encephalomyelitis
Interventions
Solriamfetol Oral Tablet [Sunosi], Placebo
Drug
Lead sponsor
Rochester Center for Behavioral Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Rochester Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Sep 12, 2026, 10:05 AM EDT
Recruiting Phase 3 Interventional

Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)

NCT07717879
View directory record Official record
Conditions
ADHD
Interventions
Solriamfetol Dose A, Solriamfetol Dose B, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
23
States / cities
Dothan, Alabama • Little Rock, Arkansas • Irvine, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 12, 2026, 10:05 AM EDT
Completed Phase 4 Interventional Results available

Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study

NCT04789174
View directory record Official record
Conditions
Excessive Daytime Sleepiness, Obstructive Sleep Apnea, Impaired Cognitive Function
Interventions
Solriamfetol, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Los Angeles, California • Santa Ana, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 12, 2026, 10:05 AM EDT
Enrolling by invitation Phase 3 Interventional

A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating Disorder

NCT06878976
View directory record Official record
Conditions
Binge-Eating Disorder
Interventions
Solriamfetol, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 56 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
33
States / cities
Encino, California • Long Beach, California • Santa Ana, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 12, 2026, 10:05 AM EDT
Recruiting Phase 3 Interventional

Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)

NCT06568367
View directory record Official record
Conditions
Excessive Sleepiness, Shift-work Disorder
Interventions
Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
44
States / cities
Auburn, Alabama • Cullman, Alabama • Chandler, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 12, 2026, 10:05 AM EDT
Completed Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)

NCT05972044
View directory record Official record
Conditions
ADHD
Interventions
Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
42
States / cities
Encino, California • Garden Grove, California • Newport Beach, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 12, 2026, 10:05 AM EDT
Not listed Phase 4 Interventional

Solriamfetol in Binge Eating Disorder

NCT04602936
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
Solriamfetol, Placebo
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Sep 12, 2026, 10:05 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Clinical Trial of Solriamfetol for Excessive Sleepiness Related to Shift Work Disorder

NCT04788953
View directory record Official record
Conditions
Excessive Sleepiness, Shift-work Disorder
Interventions
Solriamfetol Oral Tablet, Placebo
Drug
Lead sponsor
Charles A. Czeisler, PhD, MD
Other
Eligibility
18 Years to 64 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Sep 12, 2026, 10:05 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults

NCT04839562
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Solriamfetol 75 MG, Solriamfetol 150 MG, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Sep 12, 2026, 10:05 AM EDT
Completed Phase 3 Interventional Results available

"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"

NCT02348593
View directory record Official record
Conditions
Narcolepsy
Interventions
JZP-110, Placebo oral tablet
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
45
States / cities
Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 12, 2026, 10:05 AM EDT
Completed Phase 3 Interventional Results available

"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"

NCT02348606
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
JZP-110, Placebo oral tablet
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
45
States / cities
Glendale, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 12, 2026, 10:05 AM EDT
Completed Phase 2 Interventional Results available

A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness

NCT03037203
View directory record Official record
Conditions
Excessive Sleepiness, Parkinson Disease
Interventions
JZP-110, Placebo
Drug · Other
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
35 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
25
States / cities
Los Angeles, California • San Diego, California • Boulder, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2020 · Synced Sep 12, 2026, 10:05 AM EDT
Completed Phase 3 Interventional Results available

"Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"

NCT02348619
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
JZP-110
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
22
States / cities
Birmingham, Alabama • Oceanside, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2019 · Synced Sep 12, 2026, 10:05 AM EDT
Recruiting Phase 3 Interventional

Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol

NCT06413433
View directory record Official record
Conditions
Binge-Eating Disorder
Interventions
Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
44
States / cities
Encino, California • Garden Grove, California • Long Beach, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 12, 2026, 10:05 AM EDT
Recruiting Phase 2 Interventional

Solriamfetol for the Treatment of Multiple Sclerosis Fatigue

NCT06170970
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis Fatigue
Interventions
Solriamfetol, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 12, 2026, 10:05 AM EDT
Completed Phase 3 Interventional

Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol

NCT06360419
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Solriamfetol 300 mg, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
40
States / cities
Little Rock, Arkansas • Bellflower, California • Encino, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Sep 12, 2026, 10:05 AM EDT
Completed Phase 2 Interventional

RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)

NCT06404099
View directory record Official record
Conditions
Long COVID, Long COVID-19, Hypersomnia
Interventions
Modafinil, Modafinil Placebo, Solriamfetol, Solriamfetol Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 12, 2026, 10:05 AM EDT